Definition
A Prescription Drug Monitoring Program (PDMP) is a state-operated electronic database that tracks the prescribing and dispensing of controlled substances, enabling prescribers and pharmacists to identify patients who may be obtaining controlled substances from multiple providers or pharmacies — and in most states, mandatory PDMP checks are required before prescribing Schedule II through IV controlled substances.
Comprehensive Definition
Prescription Drug Monitoring Programs (PDMPs) are state-run electronic surveillance systems that collect data on controlled substance prescriptions dispensed by pharmacies within the state. Every state except Missouri now operates a PDMP, and most states have enacted mandatory check requirements that require prescribers to query the PDMP before prescribing Schedule II, III, or IV controlled substances. PDMPs are the primary tool for identifying "doctor shopping" — the practice of obtaining controlled substance prescriptions from multiple providers without each provider's knowledge.
When a pharmacy dispenses a controlled substance, it submits a report to the state PDMP database, typically within 24 to 72 hours of dispensing (though real-time reporting is increasingly required). The report includes the patient's name, date of birth, address, the drug dispensed, the quantity, the days' supply, the prescriber's DEA number, and the pharmacy's information. Prescribers and pharmacists who are registered with the PDMP can query the database to see a patient's controlled substance prescription history across all prescribers and pharmacies in the state.
Most states now require prescribers to check the PDMP before prescribing Schedule II controlled substances (and often Schedule III and IV as well), with exceptions for certain settings (emergency departments, hospice, veterinary practice) and certain prescription types (single-dose inpatient administration). The mandatory check requirement is enforced through state medical board and pharmacy board disciplinary actions, and failure to check the PDMP before prescribing is increasingly cited as a basis for prescriber discipline and civil liability.
Interstate data sharing has significantly expanded the utility of PDMPs. The PMP InterConnect program, operated by the National Association of Boards of Pharmacy (NABP), enables real-time data sharing between participating state PDMPs. As of 2025, the majority of states participate in PMP InterConnect, allowing prescribers to see a patient's controlled substance history from other states in a single query. This is particularly important in border areas and for patients who travel between states.
The DEA's relationship with PDMPs is primarily through the Controlled Substances Act (21 U.S.C. § 801 et seq.) and DEA registration requirements. DEA registrants (prescribers and pharmacies) are required to comply with state PDMP laws as a condition of their DEA registration. The DEA does not operate a national PDMP, though there have been ongoing discussions about federal PDMP legislation.
Why It Matters
PDMP compliance is not optional for prescribers of controlled substances. In most states, failure to check the PDMP before prescribing is a violation of state law that can result in medical board discipline, license suspension, and civil liability. Prescribers who continue to prescribe controlled substances to patients who are clearly obtaining them from multiple providers — a pattern that would be visible in the PDMP — face significant legal and regulatory exposure.
Beyond compliance, PDMP data is a critical clinical tool. A patient who presents requesting opioids for chronic pain may have a PDMP history showing prescriptions from five different providers in the past 30 days — a pattern that should prompt a very different clinical response than a patient with no prior controlled substance history. PDMP data can also identify patients who are at high risk for opioid overdose, enabling prescribers to intervene with naloxone prescriptions, referrals to addiction treatment, or changes in prescribing practice.
For healthcare operators — including medical directors of pain management clinics, urgent care centers, and telehealth platforms — PDMP compliance is a critical component of the compliance program. A medical director who oversees prescribers who are not checking the PDMP faces personal liability exposure in addition to the liability exposure of the prescribers themselves. Building PDMP check requirements into clinical workflows, documenting PDMP checks in the medical record, and auditing compliance are essential practices.
Historical Background
The first PDMP was established in California in 1939, initially focused on tracking Schedule II controlled substances. The modern PDMP era began in the 1990s as states responded to growing concerns about prescription drug abuse. The federal government provided significant support for PDMP development through the Harold Rogers Prescription Drug Monitoring Program, established by Congress in 2002 and administered by the Bureau of Justice Assistance.
The opioid epidemic of the 2000s and 2010s dramatically accelerated PDMP adoption and strengthened mandatory check requirements. The Comprehensive Addiction and Recovery Act (CARA) of 2016 and the SUPPORT for Patients and Communities Act of 2018 included provisions to strengthen PDMPs and expand interstate data sharing. By 2020, all states except Missouri had operational PDMPs, and most had enacted mandatory check requirements.
Federal Regulations
Controlled Substances Act: 21 U.S.C. § 801 et seq. Establishes the federal framework for controlled substance scheduling, prescribing, and dispensing. DEA registrants must comply with state PDMP laws as a condition of their registration.
Harold Rogers Prescription Drug Monitoring Program: 34 U.S.C. § 10701 et seq. Federal grant program administered by the Bureau of Justice Assistance that funds state PDMP development and enhancement.
SUPPORT for Patients and Communities Act: Pub. L. 115-271 (2018). Includes provisions to strengthen PDMPs, expand interstate data sharing, and require PDMP checks for prescribers in certain federal programs.
DEA Regulations: 21 CFR Part 1306. Governs the prescribing and dispensing of controlled substances by DEA registrants, including requirements for valid prescriptions and prescriber-patient relationships.
State Considerations
PDMP requirements vary significantly by state. Most states require prescribers to check the PDMP before prescribing Schedule II controlled substances; many also require checks for Schedule III and IV. Some states require checks for all controlled substances. Mandatory check requirements typically include exceptions for emergency situations, hospice care, and single-dose inpatient administration.
Florida operates one of the most comprehensive PDMPs in the country — E-FORCSE (Electronic-Florida Online Reporting of Controlled Substance Evaluation) — with mandatory check requirements for both prescribers and dispensers. New York's Internet System for Tracking Over-Prescribing (I-STOP) requires real-time PDMP checks before prescribing Schedule II, III, and IV controlled substances. California's CURES 2.0 system requires prescribers to check the PDMP before prescribing Schedule II, III, and IV controlled substances.
Telehealth prescribers face particular PDMP compliance challenges because they may be prescribing to patients in multiple states, each with its own PDMP and mandatory check requirements. Telehealth platforms that enable controlled substance prescribing must ensure that prescribers are registered with and checking the PDMP in each state where they prescribe.
Common Mistakes
- Not registering with the state PDMP before prescribing controlled substances — registration is required in most states and must be completed before the prescriber can query the database.
- Failing to check the PDMP before each controlled substance prescription, even for established patients — most state mandatory check requirements apply to every prescription, not just new patients.
- Not documenting PDMP checks in the medical record — documentation of the PDMP check, including the date of the check and the findings, is essential for demonstrating compliance in the event of a board investigation or malpractice claim.
- Ignoring red flags in PDMP data — a patient with a history of obtaining controlled substances from multiple providers is a significant red flag that requires a clinical response, not just documentation.
- Not registering with PDMPs in all states where the prescriber practices — telehealth prescribers and multi-state practitioners must be registered with and checking the PDMP in every state where they prescribe controlled substances.
- Assuming that interstate data sharing is automatic — not all states participate in PMP InterConnect, and even participating states may have data sharing gaps. Prescribers should understand the limitations of interstate data sharing in their practice states.
Operator Insight
PDMP compliance is one of the areas where I see the most preventable regulatory problems in healthcare businesses. The requirements are clear, the tools are available, and the consequences of non-compliance are severe — yet I regularly encounter practices where PDMP checks are not being done consistently, not being documented, or not being done at all for telehealth patients in other states. The solution is to build PDMP checks into the clinical workflow at the system level, not to rely on individual prescriber compliance. If your EHR has a PDMP integration, use it — it makes the check automatic and documents it in the medical record simultaneously. If your EHR does not have a PDMP integration, build a workflow that requires the prescriber to document the PDMP check before a controlled substance prescription can be finalized. For medical directors overseeing prescribers, PDMP compliance should be a standing item in your compliance audits. Pull a sample of controlled substance prescriptions each month and verify that PDMP checks were documented. If you find gaps, address them immediately — a pattern of non-compliance is far more damaging than an isolated failure.
— AJ Pakpour, Healthcare Practice Startup & Strategy Expert
In Practice
A pain management clinic implements a PDMP compliance workflow that requires prescribers to query the state PDMP and document the results in the EHR before any controlled substance prescription is finalized. During a routine audit, the compliance coordinator identifies that one prescriber has been documenting PDMP checks but not actually querying the database — the documentation was being added manually without a corresponding query. The prescriber is retrained, and the workflow is modified to require the PDMP query to be completed through the EHR integration before the documentation field becomes available. A telehealth platform that enables prescribing of Schedule IV controlled substances (primarily benzodiazepines for anxiety) discovers that its prescribers are checking the PDMP in the patient's home state but not in the prescriber's state. After consulting with a healthcare attorney, the platform determines that prescribers must check the PDMP in both the patient's state and the prescriber's state where required. The platform updates its prescribing workflow to require dual-state PDMP checks for all controlled substance prescriptions.
Frequently Asked Questions
References
Further Reading
Recommended Professional References
The following authoritative resources are recommended for healthcare professionals, clinic owners, compliance officers, and entrepreneurs working in this area. Links open official external websites.
Turn Knowledge Into Action
Apply what you just learned. Book a strategy session with AJ Pakpour — healthcare practice startup and strategy expert.
Book a Strategy Session